Evidence map›Paper›PMID 35099061›Full record

ArticleEuropean journal of immunology2022

SARS-CoV-2 infection activates dendritic cells via cytosolic receptors rather than extracellular TLRs.

Lieve E H van der Donk, Julia Eder, John L van Hamme, Philip J M Brouwer, Mitch Brinkkemper, Ad C van Nuenen, Marit J van Gils, Rogier W Sanders, Neeltje A Kootstra, Marta Bermejo-Jambrina and 1 more

Open access · hybridAbstract read
In one paragraph

Article in European journal of immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Lieve E H van der DonkDepartment of Experimental Immunology, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0001-7778-9853
Julia EderDepartment of Experimental Immunology, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
John L van HammeDepartment of Experimental Immunology, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Philip J M BrouwerDepartment of Medical Microbiology, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Mitch BrinkkemperDepartment of Medical Microbiology, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Ad C van NuenenDepartment of Experimental Immunology, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Marit J van GilsDepartment of Medical Microbiology, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Rogier W SandersDepartment of Medical Microbiology, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Neeltje A KootstraDepartment of Experimental Immunology, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Marta Bermejo-JambrinaDepartment of Experimental Immunology, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Teunis B H GeijtenbeekDepartment of Experimental Immunology, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-5710-2839
Amsterdam University Medical Centers · NLZero to Three · USCornell University · US

Funding

European Research Council 670424
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), an infectious disease characterized by strong induction of inflammatory cytokines, progressive lung inflammation, and potentially multiorgan dysfunction. It remains unclear how SARS-CoV-2 infection leads to immune activation. The Spike (S) protein of SARS-CoV-2 has been suggested to trigger TLR4 and thereby activate immunity. Here, we have investigated the role of TLR4 in SARS-CoV-2 infection and immunity. Neither exposure of isolated S protein, SARS-CoV-2 pseudovirus nor primary SARS-CoV-2 isolate induced TLR4 activation in a TLR4-expressing cell line. Human monocyte-derived DCs express TLR4 but not angiotensin converting enzyme 2 (ACE2), and DCs were not infected by SARS-CoV-2. Notably, neither S protein nor SARS-CoV-2 induced DC maturation or cytokines, indicating that both S protein and SARS-CoV-2 virus particles do not trigger extracellular TLRs including TLR4. Ectopic expression of ACE2 in DCs led to efficient infection by SARS-CoV-2 and, strikingly, efficient type I IFN and cytokine responses. These data strongly suggest that not extracellular TLRs but intracellular viral sensors are key players in sensing SARS-CoV-2. These data imply that SARS-CoV-2 escapes direct sensing by TLRs, which might underlie the lack of efficient immunity to SARS-CoV-2 early during infection.

Indexed as

COVID-19Dendritic CellsSpike Glycoprotein, CoronavirusToll-Like Receptor 4Cell LineHumansSARS-CoV-2Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2TLR4 protein, humanToll-Like Receptor 4Dendritic cellsInnate immune responseIntracellular viral sensorsSARS-CoV-2Toll-like receptor 4

Identifiers

PMID35099061
PMCPMC9015339
OpenAlexW4210655750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.